Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NeuroAiD
- Development stage
- Phase 4
- Lead developer
- Moleac
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
NeuroAiD is a multi-ingredient therapeutic agent derived from Traditional Chinese Medicine (TCM), developed by Moleac for the treatment of neurological deficits and functional recovery following stroke and other neurological conditions. The original formulation, MLC601, consists of nine herbal and five animal components, while the simplified version, MLC901 (NeuroAiD II), contains nine herbal components. It is characterized by neuroprotective and neurorestorative properties, including the promotion of neurogenesis, synaptogenesis, and axonal sprouting. Clinical evidence, notably from the CHIMES and CHIMES-E trials, suggests that NeuroAiD improves functional independence and neurological outcomes in patients recovering from ischemic stroke. It has also been investigated for spinal cord injury, dementia, and cognitive impairment in Alzheimer's disease.
- Brand names
- NeuroAiDNeuroAiD II
- Other names
- Chinese Medicine NeuroAidMLC601MLC-601MLC 601MLC901MLC-901MLC 901
02
Targets
KATP channel (ATP-sensitive potassium channel)BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on NeuroAiD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuroAiD.